logo
Resident stunned as trail cameras capture images of elusive creature prowling backyard: 'Like hitting the lottery'

Resident stunned as trail cameras capture images of elusive creature prowling backyard: 'Like hitting the lottery'

Yahoo7 days ago
Bobcats are the most common wildcats in America, yet they're also rarely seen by anyone outside of a zoo. As home security technology continues to become more prevalent, however, that's beginning to change.
Ring camera doorbells, home security cameras, and cellular or Wi-Fi trail cameras are doing what humans struggle with — spotting bobcats. "It's like hitting the lottery," said David Crockett, Animal Control Officer in Lynnfield, Massachusetts, according to Itemlive.
It was a trail camera that captured an image of the elusive wildcat in a Lynnfield resident Steve Fantone's backyard, an extremely rare find despite the bobcat's extensive range, which spans the southern provinces of Canada, through all 48 contiguous states, and into Mexico.
"It was similar in size to a small or medium-sized dog," Fantone said. "Bobcats have always been here because it's a habitat that has things for them to eat, like mice and birds and I have some video showing one stalking a rabbit.
This is what makes trail cameras so important in several ways, well beyond just spotting evasive bobcats. They offer a noninvasive method for scientists to study animals, their behavior, patterns, long-term data collection, and habitat use.
We've long known that human presence affects animal behavior, as a study published in the Journal of Zoological and Botanical Gardens shows.
From a conservationist perspective, trail cameras are powerful tools of discovery, contributing to population monitoring, demographics, abundance, density, human encroachment, diseases, invasive species, anti-poaching, and general evidence collection.
The information gathered from a single trail camera is enormously helpful in these efforts. Now, imagine several of them strategically spread out across a geographic area.
These smart measures, coupled with ever-advancing technologies, help preserve these animals, ensuring their longevity, health, and rehabilitation when necessary.
Animals exist on countless interconnected food chains, from primary producers to primary and secondary consumers, and so on. Remove one species from the equation, and it potentially mimics the game of Jenga, with everything crashing down in chaos.
Do you worry about air pollution in your town?
All the time
Often
Only sometimes
Never
Click your choice to see results and speak your mind.
Pollinators, plants, herbivores, carnivores, omnivores, etc., each impacting the next in positive or negative ways. A trail camera can record this information without meddling with the cycles.
The bobcat is a primary example of this. Human intervention, if only to observe from a quiet, camouflaged viewpoint, creates a disturbance that elusive, solitary animals can detect. It's difficult to spot a bobcat in person for a reason.
"Real wildlife is happening all around us. We've pushed them out of their environment," Crockett continued. Wildlife persists, and ultimately, conservation efforts will continue to strive for healthier and more diverse ecosystems.
Join our free newsletter for good news and useful tips, and don't miss this cool list of easy ways to help yourself while helping the planet.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Tornado touches down in a Chinese geological park
Tornado touches down in a Chinese geological park

Yahoo

time22 minutes ago

  • Yahoo

Tornado touches down in a Chinese geological park

STORY: :: August 4, 2025 :: A tornado touches down near a geological park in Inner Mongolia :: Ulanqab, China The footage obtained by Reuters showed clouds swirling above the narrow brown tornado column as the vortex of strong wind gusts sent debris flying everywhere. Reuters was able to verify the location of the footage from the utility tower, building exterior, road layout and terrain which matched file and satellite images. Date of footage was verified by a state media report. No casualties were reported from the incident, according to the state media report.

Market Shifts Toward Targeted Therapies as Advances in Calcium Metabolism Research Drive Development of More Effective Treatments
Market Shifts Toward Targeted Therapies as Advances in Calcium Metabolism Research Drive Development of More Effective Treatments

Yahoo

time22 minutes ago

  • Yahoo

Market Shifts Toward Targeted Therapies as Advances in Calcium Metabolism Research Drive Development of More Effective Treatments

Calcinosis Cutis is a rare disorder marked by calcium deposits in the skin, often linked to autoimmune diseases like dermatomyositis, systemic sclerosis, and lupus, as well as chronic kidney disease. Symptoms include painful, nodular formations that can lead to complications such as ulcers or restricted movement. Treatment focuses on addressing underlying conditions using phosphate binders, bisphosphonates, or surgery. The market is expanding due to rising autoimmune cases and advances in treatment, despite challenges like high costs and lack of standardized protocols. Key players like Amgen and Pfizer are innovating targeted therapies for better patient outcomes. Dublin, Aug. 05, 2025 (GLOBE NEWSWIRE) -- The "Calcinosis Cutis Market - A Global and Regional Analysis: Analysis and Forecast, 2025-2035" report has been added to global Calcinosis Cutis market is highly competitive, with several key players driving innovation and market growth. Companies such as Amgen Inc., MediGene Inc., UCB Pharma, Pfizer Inc., AbbVie Inc., Mundipharma, Vertex Pharmaceuticals, and Medtronic are leading the way in developing treatments for calcinosis cutis. These companies are focusing on various treatment approaches, including phosphate binders, biologic agents, and targeted therapies to manage the condition, which is often associated with autoimmune diseases, chronic kidney disease, and metabolic companies are investing in research to better understand the pathophysiology of calcinosis cutis and its connection to underlying diseases like systemic sclerosis and dermatomyositis. With the growing demand for more effective calcium metabolism regulation therapies, these organizations are innovating new solutions that can help slow the progression of the disease, manage symptoms, and improve patient outcomes. As the understanding of calcinosis cutis expands, these players continue to enhance drug development and improve treatment options for affected patients of the key drivers of the calcinosis cutis market is the increasing prevalence of autoimmune diseases, such as scleroderma, dermatomyositis, and lupus, which are strongly associated with the development of calcinosis cutis. As the incidence of these diseases rises, so does the demand for effective treatments for calcium deposits in the skin and soft tissues. Additionally, the growing awareness and diagnostic capabilities around chronic kidney disease and metabolic disorders, which often lead to metastatic calcinosis, are further driving the market. With advancements in treatment options, such as phosphate binders, bisphosphonates, and targeted therapies, there is an increasing demand for solutions to manage calcinosis cutis and improve patient outcomes. The development of personalized and more effective therapies, aimed at addressing the root causes of calcinosis cutis, is also contributing to the growth of the the growth of the Calcinosis Cutis market, several challenges continue to hinder progress. One of the major challenges is the lack of standardized treatment protocols for the condition. Due to the diverse underlying causes of calcinosis cutis, including autoimmune diseases, kidney disorders, and idiopathic cases, there is no one-size-fits-all treatment approach. This complexity makes it difficult for healthcare providers to offer consistent, effective treatments. Additionally, many of the existing therapies, such as bisphosphonates and phosphate binders, have limited effectiveness and may come with side effects, further complicating patient management. Moreover, high treatment costs, particularly for biologic therapies and targeted treatments, pose barriers to accessibility, especially in low-income regions or for patients with limited insurance coverage. The complexity of diagnosis, which often requires a combination of advanced imaging and tissue biopsies, also contributes to delayed diagnosis and intervention, limiting the overall impact of available global calcinosis cutis market is experiencing several key emerging trends. One significant trend is the increased focus on targeted therapies that aim to address the underlying causes of calcium deposition in tissues. Researchers and pharmaceutical companies are developing treatments that target specific mechanisms involved in calcium metabolism and phosphate regulation. This trend is driven by a deeper understanding of the disease's pathophysiology, particularly in relation to autoimmune diseases like scleroderma and dermatomyositis, as well as chronic kidney disease. Targeted therapies, such as phosphate binders, bisphosphonates, and calcification inhibitors, are showing promise in managing the condition more effectively than traditional therapies, offering potential benefits like reduced side effects and improved patient there is a growing interest in the use of combination therapies that can address both the symptoms and the underlying causes of calcinosis, providing a more comprehensive approach to treatment. This shift toward targeted and personalized treatments is expected to drive the next phase of growth in the calcinosis cutis market, enabling more precise and effective management of the Topics Covered:1. Global Calcinosis Cutis Markets: Industry Outlook1.1 Introduction1.2 Market Trends1.3 Regulatory Framework1.4 Epidemiology Analysis1.5 Clinical Trial Analysis1.6 Market Dynamics1.6.1 Impact Analysis1.6.2 Market Drivers1.6.3 Market Challenges1.6.4 Market Opportunities2. Global Calcinosis Cutis Market (Region), ($Million), 2023-20352.1 North America2.1.1 Key Findings2.1.2 Market Dynamics2.1.3 Market Sizing and Forecast2.1.3.1 North America Calcinosis Cutis Market, by Country2.1.3.1.1 U.S.2.2 Europe2.2.1 Key Findings2.2.2 Market Dynamics2.2.3 Market Sizing and Forecast2.2.3.1 Europe Calcinosis Cutis Market, by Country2.2.3.1.1 Germany2.2.3.1.2 U.K.2.2.3.1.3 France2.2.3.1.4 Italy2.3 Asia Pacific2.3.1 Key Findings2.3.2 Market Dynamics2.3.3 Market Sizing and Forecast2.3.3.1 Asia Pacific Calcinosis Cutis Market, by Country2.3.3.1.1 China2.3.3.1.2 Japan2.4 Rest of the World2.4.1 Key Findings2.4.2 Market Dynamics2.4.3 Market Sizing and Forecast3. Global Calcinosis Cutis Market: Competitive Landscape and Company Profiles3.1 Key Strategies and Development3.1.1 Mergers and Acquisitions3.1.2 Synergistic Activities3.1.3 Business Expansions and Funding3.1.4 Product Launches and Approvals3.1.5 Other Activities3.2 Company Profiles3.2.1 Overview3.2.2 Top Products / Product Portfolio3.2.3 Top Competitors3.2.4 Target Customers/End-Users3.2.5 Key Personnel3.2.6 Analyst View Laboratory Corporation of America Holdings Inozyme Pharma, Inc. Medtronic plc Pfizer Inc. Amgen Inc. Vertex Pharmaceuticals UCB Pharma For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

FTSE 100 LIVE: Markets head higher again as earnings season rolls on
FTSE 100 LIVE: Markets head higher again as earnings season rolls on

Yahoo

time22 minutes ago

  • Yahoo

FTSE 100 LIVE: Markets head higher again as earnings season rolls on

The FTSE 100 (^FTSE) and European stocks gained after the opening bell in London, buoyed for a second day as the recovery from last week's selloff continues and traders digest a slew of corporate earnings. In London, Tuesday morning saw earnings reports from oil major BP (BP.L) and drinks kingpin Diageo (DGE.L) amid a more upbeat mood following a worrying US jobs report on Friday, which missed economists' expectations. Markets are also looking to the Bank of England's next rate-setting meeting on Thursday, where a rate cut is being priced in. The cut would bring interest rates to their lowest levels in two and a half years. London's premier index opened 0.3% higher. Medical equipment manufacturer Smith & Nephew (SN.L) rose the most in the index after announcing a $500m share buyback programme. The more domestically-focused FTSE 250 (^FTMC) was 0.4% higher. The DAX (^GDAXI) in Germany gained 0.7%. Over in France, the CAC 40 (^FCHI) rose 0.4%. Meanwhile the pan-European STOXX 600 (^STOXX) headed 0.4% into the green. Hugo Boss beats Q2 expectations Reuters reported: Here's the BP chart BP reports $2.4bn second-quarter profit Yahoo Finance UK reporter Pedro Goncalves writes: BP (BP.L) reported second-quarter earnings on Tuesday that exceeded analyst expectations, as the oil major seeks to rebuild credibility with investors following a prolonged period of lagging performance relative to its peers. The company posted underlying replacement cost profit — its preferred measure of net income — of $2.35bn for the three months to June, comfortably ahead of the $1.81bn forecast by analysts, according to a consensus compiled by LSEG (LSEG.L). The figure compares with net profit of $2.76bn in the same quarter a year earlier, and $1.38bn in the first three months of 2025. Its quarterly dividend will rise to 8.32 cents from 8 cents and it will keep the pace of its share buyback programme at $750m for the second quarter, it said. The results come amid efforts by BP to regain market confidence, after strategic shifts and leadership changes left shareholders uncertain about the group's long-term direction. Read more on Yahoo Finance UK Palantir stock surges after company reports first billion-dollar quarter From our US team: Palantir (PLTR) stock surged in premarket on Tuesday after the company reported second quarter results that beat analyst estimates across the board as its revenue topped $1 billion in a quarter for the first time. "The growth rate of our business has accelerated radically," Palantir CEO Alex Karp said. "Yet we see no reason to pause, to relent, here." Shares in the defense technology giant were up more than 4% in after-hours trade on Monday. In its second quarter, Palantir posted earnings per share of $0.16, beating consensus estimates of $0.14 and up 77% from the same quarter last year. Revenue came in at $1.004bn, Palantir's first quarter surpassing the billion-dollar mark on a quarterly basis. The company's top line also beat analyst forecasts for $939.25 billion and was up 48% year over year. US commercial revenue came in at $306m, growing 93% year over year, while US government revenue for the quarter was $426m, up 53% from the same quarter last year. Analysts had estimated that sales for the two sectors would come in at $273m and $391m, respectively. Read more on Yahoo Finance Here's the US stock futures chart US stock futures make small gains as Wall Street continues recovery Our US team writes: US stock futures pushed up as Wall Street regained its balance after a tumultuous week and braced for the next wave of corporate earnings. Futures attached to the Dow Jones Industrial Average (YM=F) and the benchmark S&P 500 (ES=F) pushed up 0.2%. while contracts on the Nasdaq 100 (NQ=F) ticked up 0.3%. On Monday, stocks sharply rebounded after tanking on Friday in the aftermath of a number of market-shaking events, including a weak jobs report, fresh tariffs, new signs of rising prices, and the firing of the commissioner of the Bureau of Labor Statistics. President Trump continued to amp up pressure on trade Monday, threatening to hike tariffs on India. Good morning! Hello from London. Lucy Harley-McKeown here, gearing up for another day of news from business and markets. Today we're watching: Quarterly reports from: Oil majors BP (BP.L) and Saudi Aramco ( Drinksmaker Diageo (DGE.L) and housebuilder Travis Perkins (TPK.L) In the US: Mariott (MAR), Pfizer (PFE), Caterpillar (CAT) In data and economic releases: Purchasing managers' indices (PMIs) for services industries from Japan, Asia, the EU, UK and USA UK car sales figures Let's get to it Hugo Boss beats Q2 expectations Reuters reported: Reuters reported: Here's the BP chart BP reports $2.4bn second-quarter profit Yahoo Finance UK reporter Pedro Goncalves writes: BP (BP.L) reported second-quarter earnings on Tuesday that exceeded analyst expectations, as the oil major seeks to rebuild credibility with investors following a prolonged period of lagging performance relative to its peers. The company posted underlying replacement cost profit — its preferred measure of net income — of $2.35bn for the three months to June, comfortably ahead of the $1.81bn forecast by analysts, according to a consensus compiled by LSEG (LSEG.L). The figure compares with net profit of $2.76bn in the same quarter a year earlier, and $1.38bn in the first three months of 2025. Its quarterly dividend will rise to 8.32 cents from 8 cents and it will keep the pace of its share buyback programme at $750m for the second quarter, it said. The results come amid efforts by BP to regain market confidence, after strategic shifts and leadership changes left shareholders uncertain about the group's long-term direction. Read more on Yahoo Finance UK Yahoo Finance UK reporter Pedro Goncalves writes: BP (BP.L) reported second-quarter earnings on Tuesday that exceeded analyst expectations, as the oil major seeks to rebuild credibility with investors following a prolonged period of lagging performance relative to its peers. The company posted underlying replacement cost profit — its preferred measure of net income — of $2.35bn for the three months to June, comfortably ahead of the $1.81bn forecast by analysts, according to a consensus compiled by LSEG (LSEG.L). The figure compares with net profit of $2.76bn in the same quarter a year earlier, and $1.38bn in the first three months of 2025. Its quarterly dividend will rise to 8.32 cents from 8 cents and it will keep the pace of its share buyback programme at $750m for the second quarter, it said. The results come amid efforts by BP to regain market confidence, after strategic shifts and leadership changes left shareholders uncertain about the group's long-term direction. Read more on Yahoo Finance UK Palantir stock surges after company reports first billion-dollar quarter From our US team: Palantir (PLTR) stock surged in premarket on Tuesday after the company reported second quarter results that beat analyst estimates across the board as its revenue topped $1 billion in a quarter for the first time. "The growth rate of our business has accelerated radically," Palantir CEO Alex Karp said. "Yet we see no reason to pause, to relent, here." Shares in the defense technology giant were up more than 4% in after-hours trade on Monday. In its second quarter, Palantir posted earnings per share of $0.16, beating consensus estimates of $0.14 and up 77% from the same quarter last year. Revenue came in at $1.004bn, Palantir's first quarter surpassing the billion-dollar mark on a quarterly basis. The company's top line also beat analyst forecasts for $939.25 billion and was up 48% year over year. US commercial revenue came in at $306m, growing 93% year over year, while US government revenue for the quarter was $426m, up 53% from the same quarter last year. Analysts had estimated that sales for the two sectors would come in at $273m and $391m, respectively. Read more on Yahoo Finance From our US team: Palantir (PLTR) stock surged in premarket on Tuesday after the company reported second quarter results that beat analyst estimates across the board as its revenue topped $1 billion in a quarter for the first time. "The growth rate of our business has accelerated radically," Palantir CEO Alex Karp said. "Yet we see no reason to pause, to relent, here." Shares in the defense technology giant were up more than 4% in after-hours trade on Monday. In its second quarter, Palantir posted earnings per share of $0.16, beating consensus estimates of $0.14 and up 77% from the same quarter last year. Revenue came in at $1.004bn, Palantir's first quarter surpassing the billion-dollar mark on a quarterly basis. The company's top line also beat analyst forecasts for $939.25 billion and was up 48% year over year. US commercial revenue came in at $306m, growing 93% year over year, while US government revenue for the quarter was $426m, up 53% from the same quarter last year. Analysts had estimated that sales for the two sectors would come in at $273m and $391m, respectively. Read more on Yahoo Finance Here's the US stock futures chart US stock futures make small gains as Wall Street continues recovery Our US team writes: US stock futures pushed up as Wall Street regained its balance after a tumultuous week and braced for the next wave of corporate earnings. Futures attached to the Dow Jones Industrial Average (YM=F) and the benchmark S&P 500 (ES=F) pushed up 0.2%. while contracts on the Nasdaq 100 (NQ=F) ticked up 0.3%. On Monday, stocks sharply rebounded after tanking on Friday in the aftermath of a number of market-shaking events, including a weak jobs report, fresh tariffs, new signs of rising prices, and the firing of the commissioner of the Bureau of Labor Statistics. President Trump continued to amp up pressure on trade Monday, threatening to hike tariffs on India. Our US team writes: US stock futures pushed up as Wall Street regained its balance after a tumultuous week and braced for the next wave of corporate earnings. Futures attached to the Dow Jones Industrial Average (YM=F) and the benchmark S&P 500 (ES=F) pushed up 0.2%. while contracts on the Nasdaq 100 (NQ=F) ticked up 0.3%. On Monday, stocks sharply rebounded after tanking on Friday in the aftermath of a number of market-shaking events, including a weak jobs report, fresh tariffs, new signs of rising prices, and the firing of the commissioner of the Bureau of Labor Statistics. President Trump continued to amp up pressure on trade Monday, threatening to hike tariffs on India. Good morning! Hello from London. Lucy Harley-McKeown here, gearing up for another day of news from business and markets. Today we're watching: Quarterly reports from: Oil majors BP (BP.L) and Saudi Aramco ( Drinksmaker Diageo (DGE.L) and housebuilder Travis Perkins (TPK.L) In the US: Mariott (MAR), Pfizer (PFE), Caterpillar (CAT) In data and economic releases: Purchasing managers' indices (PMIs) for services industries from Japan, Asia, the EU, UK and USA UK car sales figures Let's get to it Hello from London. Lucy Harley-McKeown here, gearing up for another day of news from business and markets. Today we're watching: Quarterly reports from: Oil majors BP (BP.L) and Saudi Aramco ( Drinksmaker Diageo (DGE.L) and housebuilder Travis Perkins (TPK.L) In the US: Mariott (MAR), Pfizer (PFE), Caterpillar (CAT) In data and economic releases: Purchasing managers' indices (PMIs) for services industries from Japan, Asia, the EU, UK and USA UK car sales figures Let's get to it Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store